GLPwatch
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
NCT05479591 · Withdrawn
Last updated 2026-05-28This study is testing how well a new insulin treatment (IDegLira) works to control blood sugar in adults with type 2 diabetes who are currently using premix insulin.
What this study is testing ClinicalTrials.gov NCT05479591 ↗
Description as written by the study sponsor.
The purpose of this study is to look at the blood sugar control in participants with type 2 diabetes previously treated with premix insulins and initiating treatment with IDegLira. Participants will get IDegLira as prescribed by study doctor regardless of participant's decision to participate in the study. Decision to initiate treatment with IDegLira will be made by study doctor independent from the study. The study will last for about 36 weeks. Participants will be asked questions about their health and diabetes treatment and lab tests as part of their normal doctor's appointment.
Treatments tested
- IDegLira also known as Xultophy Drug
Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
| Main thing measured | Change in Glycated Haemoglobin A1c (HbA1c) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05479591 ↗